Sermorelin vs Tesamorelin: evidence, safety and FDA status

PepsRadar · Comparison · AI-assisted, written from the checked facts on each profile · Content updated October 11, 2026 (how dates work) · Not reviewed by a medical professional

The short answer

Both are versions of growth-hormone-releasing hormone (GHRH). Tesamorelin (Egrifta) is FDA-approved for one use: reducing excess abdominal fat in people with HIV-associated lipodystrophy. Sermorelin (Geref) was approved for children with growth hormone deficiency but is no longer marketed.

Key differences

Tesamorelin has randomized trials: visceral fat fell 15.2% with tesamorelin and rose 5.0% with placebo, and a later trial lowered liver fat.
Sermorelin’s main human evidence is an older open-label study in children, where growth rate rose from 4.1 to 7.2 cm a year.
Tesamorelin raises IGF-1 and can cause joint pain, swelling, injection-site reactions and higher blood sugar.
Neither is approved as a general weight-loss, anti-aging or muscle-building medicine.

Side by side

Fact	Sermorelin	Tesamorelin
FDA status	Was FDA-approved; no longer marketed	FDA-approved
Half-life	Not on an FDA label	About 8 minutes (FDA label, EGRIFTA SV ↗)
What it is	Sermorelin is a growth-hormone-releasing-hormone fragment with a historical pediatric medicine record. That history needs to be distinguished from current wellness marketing.	Tesamorelin is a prescription peptide for excess abdominal fat in HIV-associated lipodystrophy. It is not a general weight-loss medicine.
Human evidence	No randomized trials · open-label study	2 randomized trials
Human safety data	Very limited. Sermorelin (Geref) was FDA-approved for children with growth hormone deficiency but is no longer marketed; older pediatric studies reported flushing and injection pain most often.	FDA label. Tesamorelin is a GHRH analog approved to reduce excess belly fat in people with HIV; it raises IGF-1 and can cause joint pain, swelling, injection-site reactions and higher blood sugar.
Boxed warning	None on the FDA label	None on the FDA label
Serious risks	None listed	Possible growth or return of cancers Raised IGF-1 levels with unknown long-term effects Fluid retention, including carpal tunnel syndrome Glucose intolerance or diabetes Allergic reactions Higher death risk if used during acute critical illness
Conditions flagged	None flagged	Diabetes or blood-sugar medicines, Cancer, now or in the past, Pregnancy or breastfeeding
Claim check	No claim check yet	No claim check yet

Each row comes from the Sermorelin and Tesamorelin profiles, where every fact links to its source. “Conditions flagged” lists the health conditions each profile’s Risks & interactions section mentions.

The human studies

Sermorelin

Geref pediatric growth study (1996)

Human open-label study · 110 previously untreated children with growth-hormone deficiency; 86 eligible for efficacy analysis.

Average height velocity increased from 4.1 cm/year at baseline to 7.2 cm/year at 12 months.

Limitation: There was no blinded placebo comparison. Growth in hormone-deficient children cannot establish anti-aging, body-composition, or performance benefits in adults.

Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. ↗

Tesamorelin

HIV-associated abdominal-fat trial (2007)

Human randomized trial · 412 people with HIV and abdominal fat accumulation; 86% were men.

Visceral fat decreased 15.2% with tesamorelin and increased 5.0% with placebo. Some lipid measures also improved. IGF-I increased by 81.0% versus a 5.0% decrease with placebo. More tesamorelin recipients withdrew because of adverse events, despite no significant overall adverse-event difference.

Limitation: Visceral-fat change is not the same as total body-weight loss. The trial population and HIV-associated condition are central; long-term cardiovascular benefit was not established by this endpoint.

Metabolic effects of a growth hormone-releasing factor in patients with HIV. ↗

HIV-associated fatty-liver trial (2019)

Human randomized trial · 61 people with HIV and a hepatic fat fraction of at least 5% were enrolled; the abstract reports 30 receiving tesamorelin and 30 placebo.

The between-group effect on hepatic fat fraction was −4.1 percentage points (95% CI −7.6 to −0.7), corresponding to a 37% relative reduction from baseline. Liver fat fraction fell below 5% in 35% versus 4%. Fasting glucose and HbA1c changes did not differ between groups at 12 months.

Limitation: The population had HIV and fatty liver; generalization beyond this group is unestablished. The primary result concerns liver fat, not proof of fewer cirrhosis complications or longer survival. The abstract calls for longer-term histology studies.

Tesamorelin in HIV-associated fatty liver · The Lancet HIV · 2019 ↗

Results from different trials are not a head-to-head comparison: the people, preparations, durations and measures differ.

Bottom line

Wellness marketing for both goes well beyond what was studied or approved. Tesamorelin’s approval covers a specific HIV-related condition; sermorelin’s pediatric record does not carry over to adults.

PepsRadar does not give doses or usage instructions, and this page is not medical advice. For a prescription medicine, talk to your prescriber or pharmacist.

Other comparisons: BPC-157 vs TB-500 · Semaglutide vs Tirzepatide · Tirzepatide vs Retatrutide · CJC-1295 vs Ipamorelin · Selank vs Semax · MOTS-c vs Elamipretide · Ipamorelin vs MK-677 · AOD-9604 vs HGH Fragment 176-191 · Thymosin alpha-1 vs Thymosin beta-4 · Tesamorelin vs CJC-1295 · GHK-Cu vs AHK-Cu · Epitalon vs Pinealon

See something wrong on this page? Report a mistake · Corrections